Posted on 08/20/2022 8:54:18 PM PDT by ConservativeMind
Kidney cancer encompasses a wide spectrum and can present with extensive metastases or just a handful. However, today all patients are treated the same. They all receive medication.
Investigators report the results of a clinical trial exploring the role of stereotactic ablative radiation therapy (SAbR) for patients with a handful of metastases, or so-called oligometastatic disease. The study represents the first clinical trial for patients with untreated oligometastatic kidney cancer.
Each year brings more than 430,000 new cases of kidney cancer worldwide and nearly 180,000 deaths, according to the World Health Organization. About 40% of patients develop metastatic disease. Metastatic kidney cancer is typically treated with immunotherapy agents or targeted drugs, which are toxic and diminish quality of life. For most patients, the disease ultimately progresses, necessitating a change in treatment, until patients exhaust their options. When metastatic, most patients eventually succumb to the disease, and the quality of their remaining time is undermined by the cancer drugs.
The phase 2 clinical trial tested SAbR, a treatment that delivers potent, narrow beams of radiation to tumors, in 23 kidney cancer patients with oligometastases (up to five metastases) at UT Southwestern and the affiliated county hospital, Parkland Health. Patients received SAbR to metastatic tumors at the outset and while the disease remained oligometastatic. Overall, 57 metastases were treated. The primary goal was to control the metastatic cancer in at least 60% of patients at one year. The study was successful with more than 90% of patients with disease control at one year without systemic therapy.
"It appears that most patients will be free of systemic therapy for at least two years," said Dr. Hannan.
None of the patients experienced serious side effects, and periodic questionnaires showed no negative impact on quality of life.
(Excerpt) Read more at medicalxpress.com ...
No serious side effects and no negative impact on quality of life.
That’s good news.
My brother died of kidney cancer at 32. At least they thought it started in his kidneys. Very low prognosis back then.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.